Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
Halozyme Therapeutics reports 2018 executive compensation
By ExecPay News
Published: March 22, 2019
Halozyme Therapeutics reported fiscal year 2018 executive compensation information on March 22, 2019.
In 2018, five executives at Halozyme Therapeutics received on average a compensation package of $3M, a 23% increase compared to previous year.
Average pay of disclosed executives at Halozyme Therapeutics
Helen I. Torley, Chief Executive Officer, received $5.8M in total, which increased by 12% compared to 2017. 36% of Torley's compensation, or $2.1M, was in stock awards. Torley also received $832K in non-equity incentive plan, $2.1M in option awards, $725K in salary, as well as $12K in other compensation.
For fiscal year 2018, the median employee pay was $199,899 at Halozyme Therapeutics. Therefore, the ratio of Helen I. Torley's pay to the median employee pay was 29 to one.
Benjamin J. Hickey, Senior Vice President and Chief Commercial Officer, received a compensation package of $3.5M. 43% of the compensation package, or $1.5M, was in stock awards.
Laurie D. Stelzer, Chief Financial Officer, earned $2M in 2018, a 6% increase compared to previous year.
Harry J. Leonhardt, General Counsel, received $1.9M in 2018, which increases by 7% compared to 2017.
Dimitrios Chondros, Chief Medical Officer, earned $1.7M in 2018.
Related executives
Helen Torley
Halozyme Therapeutics
Chief Executive Officer
Laurie Stelzer
Halozyme Therapeutics
Chief Financial Officer
Harry Leonhardt
Halozyme Therapeutics
General Counsel
Dimitrios Chondros
Halozyme Therapeutics
Chief Medical Officer
Benjamin Hickey
Halozyme Therapeutics
Former Senior Vice President, Chief Commercial Officer
You may also like
Source: SEC filing on March 22, 2019.